Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 17, 2017

FDA permits marketing of Reset mobile application for SUD

The US Food and Drug Administration (FDA) has permitted Pear Therapeutics to market the mobile medical application, Reset, to aid substance use disorder (SUD) treatment.

The US Food and Drug Administration (FDA) has permitted Pear Therapeutics to market the mobile medical application, Reset, to aid substance use disorder (SUD) treatment.

The Reset mobile medical application system is indicated for alcohol, cocaine, marijuana and stimulant SUDs, but not for treatment of opioid dependence.

Designed to be used in conjunction with outpatient therapy and a contingency management system commonly used to treat SUDs, the Reset features a patient application and clinician dashboard.

The device provides cognitive behavioural therapy to patients by teaching skills that help to enhance abstinence from substance abuse and elevate retention of outpatient therapy programmes.

FDA Centre for Devices and Radiological Health Neurological and Physical Medicine Devices division director Carlos Peña said: “This is an example of how innovative digital technologies can help provide patients access to additional tools during their treatment.

"Results indicated a statistically significant increase of 40.3% in adherence to abstinence for the patients who used Reset, compared to 17.6% in the standard treatment group."

“More therapy tools mean a greater potential to help improve outcomes, including abstinence, for patients with substance use disorder.”

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

The FDA permit is based on the data obtained during a multi-centre, unblinded 12-week clinical trial performed in 399 subjects who received standard treatment in combination with the desktop-based version of Reset or standard treatment alone.

Results indicated a statistically significant increase of 40.3% in adherence to abstinence for the patients who used Reset, compared to 17.6% in the standard treatment group.

The Reset device is indicated as a prescription-only adjunct treatment for SUD patients who are not currently on opioid replacement therapy, and for people who do not solely abuse alcohol or opioids.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU